Posted by Michael Wonder on 25 Jun 2025
Novadip receives RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia
23 June 2025 - Novadip Biosciences is developing NVD003, an autologous therapy derived from adipose stem cells, as a potential single treatment to save limbs and restore mobility in patients with congenital pseudarthosis of the tibia.
Novadip Biosciences today announces that the FDA has granted the regenerative medicine advanced therapy designation to its tissue regeneration product, NVD003, for the treatment of congenital pseudarthosis of the tibia.
